{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-216777","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-05-11T20:10:44+00:00","discovered_at":"2026-05-11T20:13:00.402887+00:00","generated_at":"2026-05-11T22:18:44.894263+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Perspective Therapeutics reports Q1 2026 net loss of $26.2M; cash raised to $271M","bullets":["Net loss $26.2M ($0.25/share) vs. $18.2M net loss in Q1 2025; R&D spend up 50% YoY to $21.4M.","Cash, equivalents & short-term investments $271M as of Mar 31, 2026, up from $145M at Dec 31, 2025; includes $164M net from Feb 2026 offering.","Cash runway expected into late 2027 to support clinical milestones; lead program VMT-α-NET advancing to Cohort 4 and meningioma cohort.","VMT01 (melanoma) dosing cohorts closed after 10 patients treated at 3.0 mCi; PSV359 (FAP) Cohort 3 open.","Chicago manufacturing site on track to complete construction in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-216777","json":"https://secwatch.observer/filing/0001193125-26-216777.json","markdown":"https://secwatch.observer/filing/0001193125-26-216777.md","text":"https://secwatch.observer/filing/0001193125-26-216777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312526216777/0001193125-26-216777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312526216777/catx-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:18:44.894263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e5af8525e4bea200cc9a8058cac32702f14fde42","claim":"Perspective Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"On May 11, 2026, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and providing recent business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000119312526216777/0001193125-26-216777-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}